Psoriasis is a chronic inflammatory disorder of the skin and joints mediated by aberrant activity of Th1 and Th17 cells. It also has been shown to be associated with an increased risk of coronary artery disease and metabolic syndrome, highlighting the associated systemic inflammation. Despite the multitude of treatment options available, some cases are still refractory to the available agents, necessitating innovative combination therapies for management. Here we report the second case of plaque psoriasis and psoriatic arthritis treated successfully with a combination of apremilast and secukinumab.
MichalekI.M.LoringB.JohnS.M.. A systematic review of worldwide epidemiology of psoriasis.J Eur Acad Dermatol Venereol.2016 Aug 30. doi: 10.1111/jdv.13854. [Epub ahead of print]
2.
LebwohlM.G.KavanaughA.ArmstrongA.W.Van VoorheesA.S.. US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.Am J Clin Dermatol.2016; 17(1): 87–97. doi: 10.1007/s40257-015-0169-x.
3.
AreseV.AlbiniP.IbbaF.PanzoneM.CervettiO.. Juvenile psoriasis: an epidemiological study of 69 cases in the universitary dermatology clinic in Turin.G Ital Dermatol Venereol.2016 Jun 30. [Epub ahead of print].
4.
RosenbachM.HsuS.KormanN.J.Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation.J Am Acad Dermatol.2010 Apr; 62(4): 655–62. doi: 10.1016/j.jaad.2009.05.048. Epub 2009 Aug 8.
5.
LonnbergA.S.SkovL.. Co-morbidity in psoriasis: mechanisms and implications for treatment.Expert Rev Clin Immunol.2017 Jan; 13(1): 27–34. Epub 2016 Jul 28.
6.
IskandarI.Y.AshcroftD.M.WarrenR.B.Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).Br J Dermatol.2016 Sep 2. doi: 10.1111/bjd.15027. [Epub ahead of print]
7.
ThaciD.KimballA.FoleyP.Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials.J Eur Acad Dermatol Venereol.2016 Aug 18. doi: 10.1111/jdv.13918. [Epub ahead of print].
8.
AbuHilalM.WalshS.ShearN.. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.J Cutan Med Surg.2016 Jul; 20(4): 313–6. doi: 10.1177/1203475416631328. Epub 2016 Feb 4.
9.
RothsteinB.E.McQuadeB.GrebJ.E.GoldminzA.M.GottliebA.B.. Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque Psoriasis.J Drugs Dermatol.2016; 15(5): 648–649.
